BLOOD PRODUCTS MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2025 - 2032)

The Global Blood Products Market is estimated to be valued at USD 38.20 Bn in 2025 and is expected to reach USD 52.69 Bn by 2032, exhibiting a compound annual growth rate (CAGR) of 4.7% from 2025 to 2032.

The global blood products market has witnessed significant growth in recent years, driven by the increasing prevalence of chronic diseases, the rising demand for blood transfusions, and advancements in blood processing and storage technologies. Blood products, including whole blood, red blood cells, platelets, plasma, and other derivatives, play a crucial role in various medical procedures and treatments. The market encompasses a wide range of products such as albumin, immunoglobulins, coagulation factors, and other plasma-derived products. As the global healthcare industry continues to evolve and the demand for life-saving blood products rises, the blood products market is poised for substantial growth in the coming years.

Market Dynamics:

The global blood products market is influenced by several key factors that drive its growth, restrain its expansion, and present opportunities for stakeholders. One of the primary drivers of the market is the increasing prevalence of chronic diseases, such as cancer, cardiovascular disorders, and hematological conditions, which often require blood transfusions and other blood-related treatments. Additionally, the growing geriatric population worldwide, coupled with the rising incidence of surgical procedures, contributes to the heightened demand for blood products. However, the market also faces certain restraints, including the high costs associated with blood collection, processing, and storage, as well as the risk of transfusion-transmitted infections. Moreover, stringent regulatory requirements and the limited shelf life of blood products pose challenges to market growth. Despite these restraints, the blood products market presents significant opportunities for growth, such as the development of advanced blood processing technologies, the increasing adoption of automation in blood banks, and the expansion of plasma-derived therapies. Furthermore, the rising demand for blood products in emerging economies, driven by improving healthcare infrastructure and increasing healthcare expenditure, offers substantial growth prospects for market players.

Key Features of the Study:

• This report provides in-depth analysis of the global blood products market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2025–2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global blood products market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Grifols, CSL Behring, Fresenius Kabi, Octapharma, Takeda Pharmaceutical Company, Sanofi, Kedrion Biopharma, Biotest AG, Mitsubishi Tanabe Pharma Corporation, HemaCare, BloodCenter of Wisconsin, Terumo BCT, Prothera Biosciences, American Red Cross, and Vitalant
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global blood products market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global blood products market

Market Segmentation

•  Product Category Insights (Revenue, USD Bn, 2020 - 2032)
• • Whole Blood
  • Blood Components
    • Red Blood Cells (RBCs)
    • Platelets
    • Plasma
    • White Blood Cells (WBCs)
    • Cryoprecipitate
  • Plasma-derived Products
    • Immunoglobulins
    • Albumin
    • Coagulation Factors
    • Hyperimmune Globulins
    • Others
•  Application Insights (Revenue, USD Bn, 2020 - 2032)
• • Hematology
  • Immunology
  • Neurology
  • Oncology
  • Hematology
  • Others
•  Technology Insights (Revenue, USD Bn, 2020 - 2032)
• • Manual Blood Collection and Processing
  • Automated Blood Collection Systems
  • Blood Fractionation and Plasma Separation
  • Pathogen Reduction Technologies
  • Precision Blood Typing and Grouping Systems
  • Others
•  Patient Demographics Insights (Revenue, USD Bn, 2020 - 2032)
• • Pediatric Patients
  • Adult Patients
  • Geriatric Patients
•  End User Insights (Revenue, USD Bn, 2020 - 2032)
• • Hospitals
  • Blood Banks
  • Ambulatory Surgical Centers
  • Transfusion Centers
  • Diagnostic Laboratories
  • Research Institutions
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
• • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC Countries
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • North Africa
    • Central Africa
• Key Players Insights
• • Grifols
  • CSL Behring
  • Fresenius Kabi
  • Octapharma
  • Takeda Pharmaceutical Company
  • Sanofi
  • Kedrion Biopharma
  • Biotest AG
  • Mitsubishi Tanabe Pharma Corporation
  • HemaCare
  • BloodCenter of Wisconsin
  • Terumo BCT
  • Prothera Biosciences
  • American Red Cross
  • Vitalant